David C. Blakey

Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology

Uma Prabhakar, Hiroshi Maeda, Eva M. Sevick‐Muraca et al. · Cancer Research · 2013 · 1.5K citations

Pharmacy, Oncology, Pharmaceutics +17

AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer

David S. Hong, Razelle Kurzrock, Youngsoo Kim et al. · Science Translational Medicine · 2015 · 440 citations · Full text

Medicine, Cancer Biology, Oncology +8

ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.

Peter D. Davis, Graeme J. Dougherty, David C. Blakey et al. · PubMed · 2002 · 231 citations

Medicine, Oncology, Pharmacology +17

New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.

Philip E. Thorpe, Philip M. Wallace, Phillip P. Knowles et al. · PubMed · 1987 · 204 citations

Life Sciences, Immunology, Pharmacology +12

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

Sarah J. Ross, Alexey S. Revenko, Lyndsey Hanson et al. · Science Translational Medicine · 2017 · 182 citations

Medicine, Oncology, Pharmacology +16